Programs in the alliance are focused on Tyk2 and STING antagonist targets, potential drivers of a wide array of autoimmune disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Nimbus Therapeutics, a biotechnology company applying deep computational expertise throughout drug discovery and development, announced today the initiation of a long-term strategic alliance with Celgene Corporation (NASDAQ: CELG) in immunology.
Under the terms of the agreement, Celgene will receive an option to acquire each program in the alliance up through a clinical inflection point. Nimbus will receive an upfront payment and potential downstream milestone payments for each program Celgene chooses to acquire. Nimbus will retain full control of research and development activities for each program prior to the program's option point. Financial terms will remain undisclosed until Celgene acquires a program.
The Nimbus programs covered under the alliance include a preclinical effort targeting Tyk2 (tyrosine kinase 2), a signal-transduction kinase for key pro-inflammatory cytokine receptors, including IL-23, IL-12 and type-I interferons. Because of its central role in the inflammatory response, Tyk2 is a high-potential target for the treatment of autoimmune disorders including rheumatoid arthritis, lupus, Crohn's disease, psoriasis and multiple sclerosis. The alliance also covers Nimbus' preclinical small-molecule STING (stimulator of interferon genes) antagonist program, which seeks to block the role played by STING in the activation of the innate immune system in lupus and other interferonopathies. Nimbus will continue to own and develop its small-molecule STING agonist program for immuno-oncology, which is not part of the agreement.
"Celgene is committed to the continued growth of our expanding immunology and inflammation pipeline, and believes that the Nimbus immunology programs, including their efforts on Tyk2 and STING antagonists, represent important additions as we work to create the next generation of drug candidates for patients with autoimmune disorders," said Rupert Vessey, F.R.C.P., D.Phil., Executive Vice President and President, Global Research and Early Development, of Celgene.
Robert Plenge, M.D., Ph.D., Vice President, Research and Early Development, and Head, Inflammation and Immunology Thematic Center of Excellence, of Celgene, added, "We are excited about the potential of the Nimbus immunology targets, which are based on compelling human genetic data. Moreover, Nimbus' robust in silico-based approach is very promising."
"We are thrilled to partner with Celgene and its world-renowned inflammation and immunology team to fuel the rapid advancement of these important potential therapeutic programs for patients," said Donald Nicholson, Ph.D., Chief Executive Officer of Nimbus. "In addition, our agreement with Celgene accelerates our growth as a company back into the clinic, while also expanding the breadth of our pipeline."
About Nimbus Therapeutics
Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts (USA). Nimbus is pioneering the application of highly advanced computational technologies to the design and development of novel treatments for substantial and underserved human diseases. The company's focus on metabolic diseases, cancer and immune-inflammatory disorders reflects the mechanistic relationship between these disorders and Nimbus' ability to rapidly tackle well-validated targets, as well as those that have proven intractable to others. The company's LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. To learn more, please visit www.nimbustx.com.
Source: Nimbus Therapeutics
To read more Press Release articles, click here.